Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Share News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Chaucer, Ricardo, Trafficmaster...

Wed, 19th May 2010 11:20

Underwriter Chaucer has reported a 3% dip in first quarter total gross written premium income to £250.1m, which KBC Peel Hunt said shows discipline."Despite a high level of losses to the Chilean and Deepwater catastrophes in Q1, the tone of Chaucer's IMS is positive," said the broker. "The group is benefitting from its sizeable motor division as well as an expected "significant increase in offshore energy rates." Engineering and automotive consultancy Ricardo has warned that markets continue to reflect the underlying weakness of economic recovery, with customers cautious and projects taking longer to close. Order intake for the four months to April was up 11%, but "still subdued". It expects current levels of activity to be similar to the second half of the last financial year.Satnav maker Trafficmaster has made a "solid" start to the year and is on course to meet expectations for 2010. Revenue to the end of April rose 5% on the previous year, although not enough new cars are being sold to support revenue growth, the group said. Consumer Services sales dropped 23% year-on-year, although business services were up 18%.Property asset manager Capital & Regional has seen signs of further stabilisation in tenant markets and expects an increase in the flow of investment opportunities later in the year.Occupancy across its three funds eased from 94.4% at the end of December to 94.2% at 31 March due as a fall in The Mall outweighed "slight" increases in both The Junction and X-Leisure.Racecourse owner Arena Leisure's trading in the year to date has been in line with expectations.The summer period is more important for Arena and at this stage remains inherently uncertain. "Visibility of forward hospitality bookings for the summer season and the September St Leger festival is limited as lead times remain short," it says.Builder and developer Gleeson's trading remains stable but it says a "sustained upturn in house sales must await a further increase in both mortgage availability and consumer confidence." In the meantime, the focus will remain on cost control and on the acquisition of low cost land in the North of England.Property group Hansteen's annualised rent roll for its wholly owned portfolio was £63.4m at 19 May, showing a yield of 8.25%, with an overall vacancy level of 26%. That compares with end December when the rent roll was £36m and an overall vacancies were 17%. The Hansteen Property Unit Trust has £18m of properties with a rent roll of £822,000 per annum and a vacancy level of 50%."While the occupier market will remain challenging in the short term, our high yield compared to borrowing costs, coupled with the substantial additional upside in the medium term from letting the vacant properties, means the prospects for the group are encouraging," the company said.Oil and ga group Melrose Resources' production in the first quarter totalled 16.6 Bcf of gas and 668 Mbbls of oil and condensate on a working interest basis, a 17% increase compared with the same period in 2009.The 2010 capital expenditure forecast remains at $142m. Approximately 40% will be spent in Bulgaria, 33% in Egypt and the remainder split between Romania, US and Turkey. Impax, the investment manager focused on environmental sector, saw its assets under management rise by 40% in the six months to March 31 as markets improved.'Evidence of improving macroeconomic conditions, particularly in the United States and in the Asia-Pacific region, has resulted in continued recovery in equity markets in recent months and strengthening investor confidence,' it said.Shares in security and surveillance company Petards fell sharply after it said it was implementing a capital reorganisation due to the share price being below the nominal value of existing ordinary shares.Drug developer Vernalis said it has enough cash to last into 2013 as it announced its intention to expand its "already broad" development pipeline during 2010 through in-licensing and acquisitions.The company said it intends to advance its in-house programmes V158411 and V158866 through pre-clinical studies and if successful then initiate phase I studies.Real estate investment trust Rugby Estates, soon to be taken over by ING UK Real Estate Income Trust, said the company's property portfolio has performed satisfactorily in 2010. The company's shares are set to be delisted in the middle of June.
More News
31 Jul 2014 15:45

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
31 Jul 2014 05:24

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
30 Jul 2014 15:27

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
30 Jul 2014 05:20

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
29 Jul 2014 15:04

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
23 Jul 2014 14:17

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

Read more
22 Jul 2014 09:49

Vernalis Third Cough Cold Product Achieves Proof-of-Concept

Read more
22 Jul 2014 09:37

Tuesday broker round-up UPDATE

Abcam: N+1 Singer places both its target price (prev.: 346p) and its sell recommendation under review. Amiad Water Systems: Oriel lowers target price from 350p to 340p and retains a buy recommendation. Ashmore Group: Espirito Santo ups target price from 371p to 404p, while downgrading to neutral.

Read more
7 Jul 2014 09:26

Monday broker round-up UPDATE

Balfour Beatty: Berenberg lowers target price from 290p to 280p and retains a buy recommendation. UBS lowers target price from 230p to 225p and keeps a neutral rating. Barclays: Citi lowers target price from 305p to 300p and keeps its sell recommendation. Clinigen: Investec cuts target price from

Read more
29 Apr 2014 09:15

UK BROKER RATINGS: HSBC Cuts Antofagasta To Neutral And Target 13%

LONDON (Alliance News) - The following UK shares received analyst recommendations Tuesday morning:
----------
FTSE 100
----------
BERENBERG INITIATES CARNIVAL PLC WITH 'BUY' - TARGET 3,000 PENCE
----------
UBS RAISES ASTRAZENECA PRICE TARGET TO 4

Read more
8 Apr 2014 10:31

STOCKS NEWS EUROPE-UK small caps slide lower

The FTSE Small Cap Index is down by 0.5 percent while the junior-listed FTSE AIM All Share Index retreats by 1.1 percent, broadly tracking a 0.8 percent drop on the blue-chip index while the mid-caps fall by 1.4 percent. Pharmaceuticals and biotech company Vernalis slips by 2.4 percent to

Read more
8 Apr 2014 09:18

Tuesday broker round-up UPDATE

API Group: Numis lowers target price from 90p to 84p, while upgrading from add to buy. Cranswick: Investec increases target price from 1315p to 1390p retaining its buy recommendation. Daisy Group: FinnCap moves target price from 175p to 185p and retains a hold recommendation. DP World: Nomura rai

Read more
1 Apr 2014 12:14

STOCKS NEWS EUROPE-AIM index slips, Vernalis outperforms

Junior-listed AIM shares slip 0.1 percent, lagging the FTSE Small Cap index, up 0.2 percent, along with the mid-caps and the blue chips, up 0.4 percent and 0.6 percent respectively. Pharmaceutical firm Vernalis climbs nearly 3 percent after it unveils full-year results ahead of market expec

Read more
1 Apr 2014 09:39

Tuesday broker round-up UPDATE

African Barrick Gold: Deutsche Bank raises target price from 240p to 310p and keeps a hold recommendation. African Minerals: Deutsche Bank lowers target price from 399p to 382p, while its buy recommendation is kept. Allergy Therapeutics: Panmure Gordon ups target price from 16p to 25p and retains

Read more
1 Apr 2014 07:52

Vernalis beats full-year targets, positive on outlook

- Full-year ahead of expectations - Cold programme progressing well - Extremely positive outlook for 2014 and beyond Biotech specialist Vernalis said its full-year performance was ahead of market expectations and the outlook for 2014 and beyond is 'extremely positive'. The pharmaceutical company

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.